Feasibility of Real Time Medication Monitoring Among HIV Infected and TB Patients in a Resource-Limited Setting

AIDS and Behavior

Volumn 20, Issue 5, 2016, Pages 1097-1107

  de Sumari de Boer, I Marion ^a   van den Boogaard, Jossy ^a   Ngowi, Kennedy M ^a   Semvua, Hadija H ^a   Kiwango, Krisanta W ^a   Aarnoutse, Rob E ^c   Nieuwkerk, Pythia T ^b   Kibiki, Gibson S ^a  

^a KILIMANJARO CLINICAL RESEARCH INSTITUTE   (Tanzania)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adherence; HIV; Real time medication monitoring; Resource limited setting; Tuberculosis

Indexed keywords

ADULT; DRUG MONITORING; FEASIBILITY STUDY; FEMALE; HIV INFECTIONS; HUMAN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PILOT STUDY; PROSPECTIVE STUDY; PSYCHOLOGY; REMINDER SYSTEM; TANZANIA; TEXT MESSAGING; TREATMENT OUTCOME; TUBERCULOSIS; UTILIZATION;

ADULT; DRUG MONITORING; FEASIBILITY STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PILOT PROJECTS; PROSPECTIVE STUDIES; REMINDER SYSTEMS; TANZANIA; TEXT MESSAGING; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84948169193     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-015-1254-0     Document Type: Article

References (54)

1. Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health. 2008;8:265.
2. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41(3):285–97.
3. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S123–7.
4. Ammassari A, Trotta MP, Shalev N, et al. Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2011;58(4):e113–5.
5. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.
6. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Suppl 3):S272–8.
7. Barclay E. Text messages could hasten tuberculosis drug compliance. Lancet. 2009;373(9657):15–6.
8. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79–87.
9. Bova CA, Fennie KP, Knafl GJ, et al. Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav. 2005;9(1):103–10.
10. Coomes CM, Lewis MA, Uhrig JD, et al. Beyond reminders: a conceptual framework for using short message service to promote prevention and improve healthcare quality and clinical outcomes for people living with HIV. AIDS Care. 2011;24(3):348–57.
11. da Costa TM, Barbosa BJ, Gomes e Costa DA, et al. Results of a randomized controlled trial to assess the effects of a mobile SMS-based intervention on treatment adherence in HIV/AIDS-infected Brazilian women and impressions and satisfaction with respect to incoming messages. Int J Med Inform. 2012;81:257–69.
12. de Boer M. Hakuna shida! The influence of costs, care, community and counseling on adherence to ARV in Kilimanjaro. 2008.
13. de Boer M. Combination antiretroviral therapy among immigrant and indigenous HIV infected patients: quality of life and treatment adherence. Dissertation University of Amsterdam, Amsterdam. 2011.
14. de Boer IM, Prins JM, Sprangers MA, Nieuwkerk PT. Using different calculations of pharmacy refill adherence to predict virological failure among HIV-infected patients. J Acquir Immune Defic Syndr. 2010;55(5):635–40.
15. de Bruin M, Viechtbauer W, Schaalma HP, et al. Standard care impact on effects of highly active antiretroviral therapy adherence interventions: a meta-analysis of randomized controlled trials. Arch Intern Med. 2010;170(3):240–50.
16. de Bruin M, Hospers HJ, van Breukelen GJ, et al. Electronic monitoring-based counseling to enhance adherence among HIV-infected patients: a randomized controlled trial. Health Psychol. 2010;29(4):421–8.
17. Evalan BV. Real time medication monitoring with optional smart reminding. Internet. 2014;2-2-2015.
18. Girard P, Sheiner LB, Kastrissios H, Blaschke TF. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm. 1996;24(3):265–82.
19. Green J, Thorogood N. Chapter 8: Analysing qualitative data. Qualitative methods for health research. London: Sage; 2004. p. 173.
20. Haberer JE, Kahane J, Kigozi I, et al. Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 2010;14(6):1340–6.
21. Haberer JE, Kwanuka J, Nansera D, et al. Real-time adherence monitoring of antiretroviral therapy among HIV-infected adults and children in rural Uganda. AIDS. 2013;27:2166–8.
22. Hettema JE, Hosseinbor S, Ingerskoll KS. Feasibility and reliability of interactive voice response assessment of HIV medication adherence: research and clinical implications. HIV Clin Trials. 2012;13(5):271–7.
23. IAPAC. Feeling watched: emotional and moral effects of Wisepill use promote adherence for adults taking antiretroviral therapy (ART) in Rural Southwestern Uganda. Adherence 2015; A decade of success, a world of opportunities. 2015.
24. Kelly JD, Giordano TP. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25(8):1137–9.
25. Lester RT, Mills EJ, Kariri A, et al. The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol. Trials. 2009;10:87.
26. Lester R, Mills E, Kariri A, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376:1838–45.
27. Lyimo RA, van den Boogaard J, Msoka E, et al. Measuring adherence to antiretroviral therapy in northern Tanzania: feasibility and acceptability of the Medication Event Monitoring System. BMC Public Health. 2011;11:92.
28. Lyimo RA, de Bruin M, van den Boogaard J, et al. Determinants of antiretroviral therapy adherence in northern Tanzania: a comprehensive picture from the patient perspective. BMC Public Health. 2012;12:716.
29. Mbuagbaw L, Thabane L, Ongolo-Zogo P, et al. The Cameroon mobile phone SMS (CAMPS) trial: a protocol for a randomized controlled trial of mobile phone text messaging versus usual care for improving adherence to highly active anti-retroviral therapy. Trials. 2011;12:5.
30. Ministry of Health and Social Welfare URoT. Manual of the National Tuberculosis and Leprosy Programme in Tanzania. 5th ed. Dar es Salaam: MoH; 2010.
31. Munro SA, Lewin SA, Smith HJ, et al. Patient adherence to tuberculosis treatment: a systematic review of qualitative research. PLoS Med. 2007;4(7):e238.
32. Nsanzimana S, Ruton H, Lowrance DW, et al. Cell phone-based and internet-based monitoring and evaluation of the national antiretroviral treatment program during rapid scale-up in Rwanda: TRACnet, 2004-2010. J Acquir Immune Defic Syndr. 2012;59(2):e17–23.
33. Orrell C, Cohen K, Mauff K, et al. A randomised controlled trial of real-time electronic adherence monitoring with text message dosing reminders in people starting first-line antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;70(3):e73–83.
34. Ortego C, Huedo-Medina TB, Llorca J, et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav. 2011;15:1381–96.
35. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.
36. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011;25(6):825–34.
37. Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45(11):1492–8.
38. Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet. 1992;22(3):238–46.
39. Sabin LL, Bachman DeSilva M, Gill CJ, et al. Improving adherence to antiretroviral therapy with triggered real-time text message reminders: the China adherence through technology study. J Acquir Immune Defic Syndr. 2015;69(5):551–9.
40. Shuter J, Sarlo JA, Kanmaz TJ, Rode R, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr. 2007;45(1):4–8.
41. Siedner MJ, Lankowski A, Musinga D, et al. Optimizing network connectivity for mobile health technologies in sub-Saharan Africa. PLoS One. 2012;7(9):e45643.
42. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S23–35.
43. van den Boogaard J. Non-adherence to tuberculosis treatment: an integral approach to measure and prevent it. Dissertation Radboud University, Nijmegen. 2011.
44. van den Boogaard J, Lyimo R, Irongo CF, et al. Community vs. facility-based directly observed treatment for tuberculosis in Tanzania’s Kilimanjaro Region. Int J Tuberc Lung Dis. 2009;13(12):1524–9.
45. van den Boogaard J, Boeree MJ, Kibiki GS, Aarnoutse RE. The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and how can we get out? Trop Med Int Health. 2011;16(6):693–8.
46. van den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ. 2011;89(9):632–9.
47. van den Boogaard J, Msoka E, Homfray M, et al. An exploration of patient perceptions of adherence to tuberculosis treatment in Tanzania. Qual Health Res. 2012;22(6):835–45.
48. Vervloet M, van Dijk L, Santen-Reestman J, et al. Improving medication adherence in diabetes type 2 patients through Real Time Medication Monitoring: a randomised controlled trial to evaluate the effect of monitoring patients’ medication use combined with short message service (SMS) reminders. BMC Health Serv Res. 2011;11:5.
49. Vervloet M, van Dijk L, de Bakker DH, et al. Short- and long-term effects of real-time medication monitoring with short message service (SMS) reminders for missed doses on the refill adherence of people with Type 2 diabetes: evidence from a randomized controlled trial. Diabet Med. 2014;31(7):821–8.
50. Vervoort SC, Borleffs JC, Hoepelman AI, Grypdonck MH. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS. 2007;21:271–81.
51. Vrijens B, Goetghebeur E. The impact of compliance in pharmacokinetic studies. Stat Methods Med Res. 1999;8(3):247–62.
52. Vrijens B, Tousset E, Rode R, et al. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J Clin Pharmacol. 2005;45(4):461–7.
53. Wilson IB, Bangsberg DR, Shen J, et al. Multisite Adherence Collaboration on HIV 14 Investigators. Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: results from the multisite adherence collaboration on HIV 14 study. J Acquir Immune Defic Syndr. 2013;64:448–54.
54. World Health Organization. Adherence to long-term therapies. Evidence for action. Geneva: WHO; 2003.